Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Combination Overcomes Breast Cancer Resistance… >
Combination Overcomes Breast Cancer Resistance to Herceptin

Published: March 14, 2011.
By University of Texas M. D. Anderson Cancer Center
http://www.mdanderson.org

HOUSTON - Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

Adding the drug saracatinib to Herceptin treatment shrinks previously resistant tumors by cutting off at least five different molecular pathways, each of which can resist, said senior author Dihua Yu, M.D., Ph.D., professor in MD Anderson's Department of Molecular and Cellular Oncology.

"Scientists have identified so many ways by which a tumor resists Herceptin that it raises an important issue for treatment," Yu said. "Will we have to give patients six drugs or 10 drugs to block them all? The side effects would be awful. Two pills are better. This combination is a promising therapy for those with Herceptin-resistant breast cancer."

Working in cell lines, mouse models of breast cancer and checking their work in human tumor samples, Yu and colleagues identified SRC, a known cancer-promoting protein, as the crucial common downstream component of multiple resistance pathways.

Saracatinib is an SRC inhibitor, thwarting that protein and allowing Herceptin to work again in tumors that have a high amount of the HER2 protein.

Only about 26 percent of women with HER2-positive breast cancer respond to Herceptin as single therapy. Between 40 and 60 percent respond to the drug when combined with other chemotherapy.

Combination is ready for clinical trials

Yu said saracatinib has been tested in phase I and phase II clinical trials as a single treatment against late-stage cancers. It has a favorable side effects profile.

"It didn't work as a single agent, but very few drugs work by themselves against late stage disease," Yu said. "Our experiments confirmed its lack of efficacy as a sole treatment. But combined with Herceptin, it's beautiful."

Another SRC inhibitor, dasatinib, has been approved by the U.S. Food and Drug Administration as an anti-cancer drug, but it has harsher side effects, said Siyuan Zhang, Ph.D., a postdoctoral fellow in Yu's lab and the paper's first author.

A tumor-suppressor's job

In 2004, Yu's lab discovered that loss of the tumor-suppressing gene known as PTEN led to Herceptin-resistant tumors. PTEN is a phosphotase - a protein whose function is to strip phosphate chemical groups off of other molecules.

PTEN has two components, one to remove phosphate groups from lipids, and another to remove them from proteins. PTEN's target protein however, was unknown.

Zhang discovered that SRC is a PTEN target. With its phosphate groups, SRC is active. PTEN stifles SRC by peeling away the phosphates.

If PTEN loss leads to Herceptin resistance, and PTEN targets SRC, would that make SRC the culprit?

On the trail of SRC

In a series of experiments the researchers found:

  • SRC is active in breast cancer cells once vulnerable but now resistant to Herceptin and in cells that are resistant from the start.
  • Activation of SRC drives resistance to Herceptin. Tumors with low SRC levels treated by Herceptin shrunk to 20 percent of their original volume in 21 days while SRC-heavy tumors increased by nearly 400 percent over the same time in mouse experiments.
  • SRC activity correlates with patient response to Herceptin. Assessing SRC activation in samples of 57 human breast cancer tumors, the team found that more than 90 percent of tumors with low SRC responded compared with 40 percent of tumors with active SRC.
  • Patients with little active SRC had a median survival of 57.9 months compared with 34.2 months in those with high SRC activity.
  • SRC is activated by a number of receptor tyrosine kinases that cause resistance, including IGF-1R, EGFR, ERBB2, HER3, and Met, separate pathways that work through SRC. "Block SRC, and you reverse them all," Zhang said.


Crushing resistance

Combining Herceptin and saracatinib to treat resistant tumors in mice reduced tumor volume by 90 percent in 25 days. Herceptin alone kept tumor volume about the same during the same period, while control and saracatinib alone permitted growth of more than 200 percent.

The difference was more striking in tumors deficient in SRC's enemy, the PTEN tumor-suppressor. The combination reduced tumor volume by more than 90 percent while the two drugs alone allowed growth of between 200 and 400 percent.

This study was funded by grants from the National Cancer Institute, MD Anderson Breast Specialized Program of Research Excellence; Department of Defense Center of Excellence; Susan G. Komen Breast Cancer Foundation Promise Grant; the Cancer Prevention and Research Institute of Texas, the MD Anderson Breast SPORE Career Development Award and Susan G. Komen Breast Cancer Foundation Postdoctoral Fellowship.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Risk 
2/10/14 
★★★★ 
Smoking Linked with Increased Risk of Most Common Type of Breast Cancer
By Wiley
Young women who smoke and have been smoking a pack a day for a decade or more have a significantly increased risk of developing the most common type of …
Cells 
1/27/14 
★★★ 

Long-lived Breast Stem Cells Could Retain Cancer Legacy
By Walter and Eliza Hall Institute
Breast 
2/15/12 
GW Researchers Reveal Digital Transcriptome of Breast Cancer
By George Washington University Medical Center
GW Cancer Research Team in the Department of Biochemistry and Molecular Biology, in the School of Medicine and Health Sciences, published a study that is the first of its …
Breast 
8/23/10 
Nicotine Binding to Receptor Linked to Breast Cancer Cell Growth
By Journal of the National Cancer Institute
When nicotine binds to the nicotinic acetylcholine receptor (nAchR), it is known to promote smoking addiction and may also directly promote the development of breast cancer, according to a …
Breast 
9/22/11 
Cellular Origin of a Rare Form of Breast Cancer Identified
By Tufts University, Health Sciences Campus
BOSTON (September 22, 2011) -- Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte …
Methylation 
12/9/13 
Breast Cancer Prognosis Associated with Oncometabolite Accumulation
By Journal of Clinical Investigation
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan …
Cancer 
2/12/14 
New Study Explains How Dense Breast Tissue Drives the Early Stages of Cancer
By Landes Bioscience
Scientists from The University of Manchester working with IBM Research have identified a key biological mechanism that for the first time explains why women with dense breast tissue are …
Luminal 
3/27/14 
Mechanical Forces Driving Breast Cancer Lead to Key Molecular Discovery
By University of California - San Francisco
The stiffening of breast tissue in breast-cancer development points to a new way to distinguish a type of breast cancer with a poor prognosis from a related, but often …
Patients 
2/7/12 
PET Techniques Provide More Accurate Diagnosis, Prognosis in Challenging Breast Cancer Cases
By Society of Nuclear Medicine
In two new studies featured in the February issue of the Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult …
Breast 
9/19/14 
Experts Issue Plea for Better Research And Education for Advanced Breast Cancer
By European Society for Medical Oncology
Breast cancer experts around the world have issued a plea to researchers, academics, drug companies, funders and advocates to carry out high quality research and clinical trials for advanced …
Cancer 
1/22/13 
LSUHSC Research Provides New Drug Target for Her-2 Related Breast Cancer
By Louisiana State University Health Sciences Center
New Orleans, LA – Research led by Dr. Suresh Alahari, the Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans and its Stanley …
Egfr 
4/20/10 
Increased EGFR Levels May Be an Early Marker of Breast Cancer
By American Association for Cancer Research
WASHINGTON, D.C. — Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis, according to …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition